Geron to Release Q3 2024 Financial Results on November 7, 2024

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a company focused on biopharmaceutical advancements, has announced plans to release its third quarter financial results and business updates for 2024. The announcement will be made public before the market opens on Thursday, November 7, 2024. This information will be accessible through a press release on the Company’s website.

In conjunction with the release, Geron will hold a conference call at 8:00 a.m. ET on the same day to discuss these financial results and business highlights. The conference call will be accompanied by a live webcast and a related presentation, both of which can be accessed on the Company’s website. For those unable to attend the live session, an archived version of the webcast will be available on the Company’s website for 30 days post-event.

Geron Corporation is a biopharmaceutical company operating at a commercial stage with a mission to transform the treatment of blood cancer. The company is known for its leading telomerase inhibitor, RYTELO™ (imetelstat), which has gained approval in the United States for use in specific adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who suffer from transfusion-dependent anemia.

Additionally, Geron is actively engaged in a pivotal Phase 3 clinical trial of imetelstat for patients with relapsed or refractory myelofibrosis (R/R MF) who have previously been treated with JAK inhibitors. The company is also exploring the use of imetelstat in other hematologic malignancies.

The therapeutic approach of Geron focuses on inhibiting the activity of telomerase, an enzyme that is often elevated in malignant stem and progenitor cells within the bone marrow. The inhibition of telomerase is intended to reduce the proliferation of these malignant cells and potentially induce their death, offering a promising treatment avenue for various blood cancers.

For more detailed information about Geron Corporation and its initiatives, interested parties are encouraged to visit the Company’s website. Geron also maintains a presence on LinkedIn for those who wish to follow their updates and developments in the biopharmaceutical field.